PL3746441T3 - Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania - Google Patents

Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania

Info

Publication number
PL3746441T3
PL3746441T3 PL19706097.3T PL19706097T PL3746441T3 PL 3746441 T3 PL3746441 T3 PL 3746441T3 PL 19706097 T PL19706097 T PL 19706097T PL 3746441 T3 PL3746441 T3 PL 3746441T3
Authority
PL
Poland
Prior art keywords
formulations
salts
preparation
methods
pharmaceutical compound
Prior art date
Application number
PL19706097.3T
Other languages
English (en)
Inventor
Karthik Nagapudi
Yuan Liu
Shuai WANG
Wei Zhang
Fritz Blatter
Srikonda Sastry
Manshiu Leung
Ramachandran Radhakrishnan
Rajendra S. Tandale
Ludwig Pilsl
Roland Muller
Markus Frieser
Christine CZAUDERNA
Lawrence Emerson Fisher
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL3746441T3 publication Critical patent/PL3746441T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/14Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19706097.3T 2018-02-02 2019-02-01 Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania PL3746441T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018075023 2018-02-02
PCT/US2019/016386 WO2019152863A1 (en) 2018-02-02 2019-02-01 Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same

Publications (1)

Publication Number Publication Date
PL3746441T3 true PL3746441T3 (pl) 2023-07-31

Family

ID=65494537

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19706097.3T PL3746441T3 (pl) 2018-02-02 2019-02-01 Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania

Country Status (18)

Country Link
US (2) US20200361933A1 (pl)
EP (1) EP3746441B1 (pl)
JP (2) JP7372926B2 (pl)
KR (2) KR20260007293A (pl)
CN (2) CN112105616B (pl)
AR (1) AR114090A1 (pl)
AU (3) AU2019215172B2 (pl)
BR (1) BR112020015759A2 (pl)
CA (1) CA3090270A1 (pl)
ES (1) ES2949662T3 (pl)
HR (1) HRP20230645T1 (pl)
IL (2) IL312673A (pl)
MX (2) MX2020008076A (pl)
PL (1) PL3746441T3 (pl)
SG (1) SG11202007726RA (pl)
SI (1) SI3746441T1 (pl)
TW (2) TW202426448A (pl)
WO (1) WO2019152863A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160410A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
CN114129517A (zh) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用
CN116509850A (zh) * 2022-01-21 2023-08-01 苏州爱科百发生物医药技术有限公司 N-芳基吡啶酮类化合物在尘肺治疗中的用途
WO2023219106A1 (ja) * 2022-05-10 2023-11-16 Myrodia Therapeutics株式会社 2-メチル-2-チアゾリンの塩

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515248A (en) * 1999-05-07 2004-01-30 Texas Biotechnology Corp Heterocyclic substituted carboxylic acid derivatives useful for inhibit the binding of integrins to their receptors
MY150746A (en) * 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
AP2011005824A0 (en) * 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
WO2010089292A1 (en) * 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
WO2011055270A1 (en) * 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US20140094456A1 (en) * 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones
CN106459042B (zh) * 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
RU2736941C2 (ru) * 2015-12-02 2020-11-23 Мерк Шарп энд Доум Корп. Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин

Also Published As

Publication number Publication date
CA3090270A1 (en) 2019-08-08
CN112105616A (zh) 2020-12-18
AR114090A1 (es) 2020-07-22
MX2020011756A (es) 2021-06-23
HRP20230645T1 (hr) 2023-09-29
AU2019215172B2 (en) 2023-08-10
MX2020008076A (es) 2020-09-24
IL276430B2 (en) 2024-10-01
AU2023222929B2 (en) 2025-09-18
KR102903080B1 (ko) 2025-12-22
AU2023222929A1 (en) 2023-09-21
CN117247383A (zh) 2023-12-19
US20240409539A1 (en) 2024-12-12
ES2949662T3 (es) 2023-10-02
KR20260007293A (ko) 2026-01-13
IL276430A (en) 2020-09-30
CN112105616B (zh) 2023-09-01
SI3746441T1 (sl) 2023-08-31
US20200361933A1 (en) 2020-11-19
KR20200118098A (ko) 2020-10-14
WO2019152863A1 (en) 2019-08-08
JP2021512118A (ja) 2021-05-13
JP7372926B2 (ja) 2023-11-01
SG11202007726RA (en) 2020-09-29
TW201940482A (zh) 2019-10-16
TW202426448A (zh) 2024-07-01
BR112020015759A2 (pt) 2020-12-08
AU2019215172A1 (en) 2020-08-20
EP3746441B1 (en) 2023-04-05
IL276430B1 (en) 2024-06-01
EP3746441A1 (en) 2020-12-09
AU2025283559A1 (en) 2026-01-15
TWI834634B (zh) 2024-03-11
JP2023145680A (ja) 2023-10-11
IL312673A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
EP4045480A4 (en) PHARMACEUTICAL FORMULATIONS
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
EP4233846C0 (en) PHARMACEUTICAL FORMULATIONS
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
DK3866767T3 (da) Farmaceutisk sammensætning til oral indgivelse omfattende aminopyrimidinderivat eller salt deraf
IL285674A (en) Pharmaceutical formulations
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
JO3683B1 (ar) صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها
PL3746441T3 (pl) Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania
DK3897589T3 (da) Farmaceutiske formuleringer indeholdende relacorilant, en heteroaryl-ketonkondenseret azadecalinforbindelse
DK3886820T3 (da) Kapselformuleringer
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
EP3868371A4 (en) Novel pharmaceutical composition
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
DK3762009T3 (da) Toxin-afledte indgivelseskonstrukter til oral indgivelse
IL282343A (en) Aqueous pharmaceutical formulations
DK4027973T3 (da) Formuleringer til lægemiddeladministration
MX390899B (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
EP3813822A4 (en) SOLID PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING TERIFLUNOMIDE
IL280118A (en) Medicinal preparation for external use
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
EP3921322C0 (en) PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
EP3651800C0 (en) HYDROCOMPRESSED PHARMACEUTICAL FORMULATIONS